Nobuhiro Ueno, Yuya Sugiyama, Yu Kobayashi, Yuki Murakami et al DOI: https://doi.org/10.21203/rs.3.rs-154609/v1
Tag: Clinical trial
Scientific corner
Fecal Calprotectin is a Useful Biomarker for Predicting the Clinical Outcome of Granulocyte and Monocyte Adsorptive Apheresis in Ulcerative Colitis Patients: A Prospective Observation Study
In summary, we demonstrated the utility of FC as a biomarker for assessing ER after GMA and predicting CR at the early phase during GMA in patients with active UC. Assessing the baseline characteristics alone before GMA was not sufficient to predict CR. Our findings will benefit patients with active UC by allowing them to avoid undergoing unnecessary invasive procedures and will help establish new GMA therapeutic strategies.
Scientific corner
Exploratory Study of the Effectiveness of Granulocyte and Monocyte Adsorptive Apheresis Before Initiation of Steroids in Patients With Active Ulcerative Colitis (EXPECT Study): A Multicenter Prospective Clinical Trial
Kazuki Kakimoto 1, Minoru Matsuura 2, Takumi Fukuchi 3, Hitoshi Hongo 4, Tsuguhiro Kimura 4, Nobuo Aoyama 5, Yorihide Okuda 6, Kazuki Aomatsu 7, Noriko Kamata 8, Yoko Yokoyama 9, Chiemi Mizuno 10, Takuya Inoue 1, Takako Miyazaki 1, Shiro Nakamura 1, Kazuhide Higuchi 1, Hiroshi Nakase 11 , Crohns Colitis 360. 2020 Sep 23;2(4):otaa073.
GMA shows effectiveness in inducing remission in UC patients not receiving steroid.
Scientific corner
Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: A multicenter cohort study
Yoh Ishiguro 1, Toshihide Ohmori 2, Ken Umemura 3, Masahiro Iizuka 4 ,Ther Apher Dial 2020 Oct 7.
GMA was an effective treatment for corticosteroid-naïve patients and the efficacy sustained longer in those not receiving immunomodulators during GMA. GMA fulfills the notion that apheresis is to induce disease remission by removing from the body factors known to perpetuate disease. In therapeutic settings, these findings should help better decision making and avoid futile use of medical resources.
Scientific corner
Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice
Takayuki Iida 1, Kentaro Ikeya, Masaichi Kato, Jinro Abe, Masayoshi Yamamoto, Fumitoshi Watanabe, Ken Sugimoto, Hiroyuki Hanai , Digestion. 2017;96(2):119-126.
Corticosteroid-naïve patients appeared to benefit the most from the Adacolumn GMA, and attain a favourable long-term clinical course. Accordingly, GMA should be a first-line therapy in this clinical setting.
Scientific corner
Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study
Takayuki Yamamoto 1, Toshiaki Tanaka 2, Tadashi Yokoyama 3, Takahiro Shimoyama 1, Hiroki Ikeuchi 4, Motoi Uchino 4, Toshiaki Watanabe 5 , Therap Adv Gastroenterol. 2017 Feb;10(2):199-206.
GMA has a good safety profile, but its efficacy appears to be limited in the management of chronic refractory pouchitis. However, a large controlled study should be conducted to evaluate the efficacy of GMA therapy in patients with pouchitis at an earlier clinical stage, before the disease has become refractory to conventional medical therapy.
antibiotic / Clinical trial / multicentre / open-label / pouchitis / proctocolectomy / prospective / Safety /
Scientific corner
Granulocyte-Monocyte Apheresis in Steroid-Dependent, Azathioprine-Intolerant/Resistant Moderate Ulcerative Colitis: A Prospective Multicenter Study.
Gianni Imperiali 1, Arnaldo Amato 1, Maria Maddalena Terpin 2, Ivo Beverina 3, Aurora Bortoli 4, Massimo Devani 4, Chiara Viganò 5,Gastroenterol Res Pract2017;2017:9728324.
Our study shows that a standard course of granulocyte-monocyte apheresis is associated with a 36% steroid-free clinical remission in patients with steroid-dependent, azathioprine-intolerant or resistant moderate ulcerative colitis. Apheresis might represent an alternative to biologic therapy or surgery in this specific subgroup of patients
Scientific corner
Adsorptive Granulocyte and Monocyte Apheresis in the Treatment of Ulcerative Colitis: The First Multicenter Study in China.
Ya-Min Lai 1, Wei-Yan Yao 2, Yao He 3, Xuan Jiang 4, Yu-Bei Gu 2, Min-Hu Chen 3, Yu-Lan Liu 4, Yao-Zong Yuan 2, Jia-Ming Qian 1 , Gut Liver. 2017 Mar 15;11(2):216-225.
The overall efficacy of GMA in patients with active UC who were taking first-line medications or were corticosteroid refractory was encouraging. Additionally, GMA was well tolerated and had a good safety profile.
Scientific corner
Retrospective Single Center Study of Granulocyte Monocyte Adsorption Apheresis Treatment in Inflammatory Bowel Disease.
Kajsa Edfors 1, Dagny Ståhlberg 1, Charlotte Söderman 1 , Ther Apher Dial. 2016 Feb;20(1):79-85.
Most frequently reported was headache (N = 4). GMA seems to be a valuable adjuvant treatment regime in the care of patients with refractory IBD.
Scientific corner
A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn’s disease.
Bruce E Sands 1, Seymour Katz, Douglas C Wolf, Brian G Feagan, Tao Wang, Lisa-Marie Gustofson, Cindy Wong, Margaret K Vandervoort, Stephen Hanauer, Gut. 2013 Sep;62(9):1288-94.
GMA was well tolerated, but this study did not demonstrate its effectiveness over a sham procedure in inducing clinical remission or response in patients with moderate to severe CD.
Scientific corner
Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone.
Keiichi Tominaga 1, Masakazu Nakano, Mina Hoshino, Kazunari Kanke, Hideyuki Hiraishi, BMC Gastroenterol. 2013 Mar 1;13:41.
In appropriately selected patients, GMA has significant efficacy with no safety concern. The higher cost of GMA vs PSL should be compromised by good safety profile of this non-pharmacological treatment intervention.
Contact UsFor more information
Contact Us